Because the overall prevalence of elevated ALT and AST is influenced by the proportion of studies enrolling patients with severe COVID-19 in meta-analyses, we think that epidemiologic data are more valuable when reported for different subpopulations stratified by severity of COVID-19. The gene discussed is GPT; the disease is COVID-19.